📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. (2023)

First Author: Vale CL

Attributed to: Method Meta-analysis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(23)00230-9

PubMed Identifier: 37414011

Publication URI: http://europepmc.org/abstract/MED/37414011

Type: Journal Article/Review

Volume: 24

Parent Publication: The Lancet. Oncology

Issue: 7

ISSN: 1470-2045